Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-07941944 in Healthy Adults
NCT06920498Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07941944 in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Pfizer. Primary endpoints: Treatment Emergent Treatment-Related Adverse Events at 16 weeks, Clinically Significant Change From Baseline in Laboratory Abnormalities at 16 weeks and 5 more. Started Dec 2024; status: completed.
02
Drugs
PF-07941944
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06920498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06920498.